The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders

• Bauke Schievink,

  Affiliation Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Hiddo Lambers Heerspink ,

  * E-mail: h.j.lambers.heerspink@umcg.nl

  Affiliation Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Hubert Leufkens,

  Affiliations Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands, Medicines Evaluation Board, Utrecht, The Netherlands

  ⨯
• Dick De Zeeuw,

  Affiliation Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Jarno Hoekman

  Affiliation Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands

  ⨯